Table 2.

Univariate and multivariate analysis of overall survival in EOC patients.

	Univariate analysis		Multivariate analysis
Variables	HR (95 % CI)	p value*	HR (95 % CI)	p value*
Age (≥ 45 vs. < 45)	1.448 (1.087–1.928)	0.011	1.215 (0.825–1.791)	0.324
CA125 (> 1000 vs. ≤ 1000)	1.313 (1.042–1.655)	0.021	1.080 (0.803–1.454)	0.610
Pathologic grade (1,2 vs. 3)	0.681 (0.492–0.943)	0.002	0.942 (0.637–1.392)	0.764
FIGO tumor stage (I, II vs. III, IV)	0.355 (0.229–0.489)	0.0001	0.467 (0.287–0.760)	0.002
Histopathology (Serous vs. other)	0.606 (0.420–0.875)	0.008	0.753 (0.421–1.348)	0.341
Pelvic lymph node metastasis (Yes vs. No)	1.783 (1.264–2.515)	0.001	NA	NA
Abdominal aorta lymph node metastasis (Yes vs. No)	2.401 (1.590–3.626)	0.0001	NA	NA
Residual disease (< 1cm vs. ≥ 1cm)	0.506 (0.375–0.683)	0.0001	0.492 (0.348–0.694)	0.0001
Treatment (CIT vs. Control)	0.536 (0.369–0.778)	0.001	0.600 (0.369–0.975)	0.039

*, Cox regression;

HR: hazard ratio; CI: confidence interval; NA: not analyzed; CIT: cellular immunotherapy.